Volker Germaschewski
YOU?
Author Swipe
View article: A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice
A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice Open
Iron plays a major role in the deterioration of β-thalassemia. Indeed, the high levels of transferrin saturation and iron delivered to erythroid progenitors are associated with production of α-globin precipitates that negatively affect ery…
View article: Data from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Data from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
The immunosuppressive tumor microenvironment constitutes a significant hurdle to immune checkpoint inhibitor responses. Both soluble factors and specialized immune cells, such as regulatory T cells (Treg), are key components of active intr…
View article: Supplementary Movie 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Movie 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Isotype control
View article: Supplementary Table 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Table 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Metadata for the 5 NSCLC patients
View article: Supplementary Table 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Table 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Genes used to define Immune cell subtypes
View article: Data from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Data from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
The immunosuppressive tumor microenvironment constitutes a significant hurdle to immune checkpoint inhibitor responses. Both soluble factors and specialized immune cells, such as regulatory T cells (Treg), are key components of active intr…
View article: Supplementary Movie 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Movie 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
AntilCOS
View article: Supplementary Figures and Tables Legend from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Figures and Tables Legend from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Figure and tables legends of supplementary data
View article: Supplementary Movie 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Movie 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
AntilCOS
View article: Supplementary Movie 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Movie 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Isotype control
View article: Supplementary Table 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Table 1 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Genes used to define Immune cell subtypes
View article: Supplementary Figures and Tables Legend from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Figures and Tables Legend from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Figure and tables legends of supplementary data
View article: Supplementary Figures from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Figures from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Supplementary Figures 1-9
View article: Supplementary Table 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Table 2 from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Metadata for the 5 NSCLC patients
View article: Supplementary Figures from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Supplementary Figures from An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
Supplementary Figures 1-9
View article: An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression Open
The immunosuppressive tumor microenvironment constitutes a significant hurdle to immune checkpoint inhibitor responses. Both soluble factors and specialized immune cells, such as regulatory T cells (Treg), are key components of active intr…
View article: A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease
A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease Open
Recombinant erythropoietin (EPO) and iron substitution are a standard of care for treatment of anemias associated with chronic inflammation, including anemia of chronic kidney disease. A black box warning for EPO therapy and concerns about…
View article: The Anti-Osteoprotegerin (OPG) Antibody Ky3 Attenuates OPG-Fas Mediated Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Pro-Inflammatory Signalling In Vitro and In Vivo
The Anti-Osteoprotegerin (OPG) Antibody Ky3 Attenuates OPG-Fas Mediated Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Pro-Inflammatory Signalling In Vitro and In Vivo Open
View article: A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Open
Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased wi…
View article: A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension Open
View article: A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression
A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression Open
The immunosuppressive tumour microenvironment constitutes a significant hurdle to the response to immune checkpoint inhibitors. Both soluble factors and specialised immune cells such as regulatory T cells (T Reg ) are key components of act…
View article: PF338 DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A
PF338 DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A Open
Background: Recently a range of alternative novel therapies have been developed to improve treatment options for patients with Hemophilia A. One approach is to generate a Factor VIII (F.VIII) mimetic molecule using a humanised bispecific a…